Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy": Five analysts average a "Moderate Buy" on Metagenomi (one sell, three buy, one strong buy) with a consensus 12‑month price target of $10.00.
• Quarterly results missed: The company reported ($0.60) EPS vs. ($0.58) expected and revenue of $3.91M vs. $7.33M expected, leaving a negative net margin of 348.54% and analysts forecasting roughly -2.46 EPS for the year.
• Institutional interest despite low valuation: BNP Paribas and Bank of America materially increased positions and several funds opened new stakes, while MGX trades around $1.40 with a market cap of about $52.7M.

Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Metagenomi from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Metagenomi in a research report on Monday, December 22nd.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its position in Metagenomi by 1,840.0% in the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company's stock valued at $36,000 after buying an additional 14,389 shares during the last quarter. Bank of America Corp DE lifted its position in Metagenomi by 508.5% in the third quarter. Bank of America Corp DE now owns 18,766 shares of the company's stock valued at $44,000 after buying an additional 15,682 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Metagenomi in the third quarter valued at about $64,000. Panagora Asset Management Inc. acquired a new position in Metagenomi in the fourth quarter valued at about $53,000. Finally, Quadrature Capital Ltd acquired a new position in Metagenomi in the fourth quarter valued at about $55,000.

Metagenomi Trading Up 1.4%

Shares of MGX stock opened at $1.40 on Tuesday. The company's 50-day moving average price is $1.46 and its 200-day moving average price is $1.84. The stock has a market cap of $52.67 million, a price-to-earnings ratio of -0.59 and a beta of 0.56. Metagenomi has a twelve month low of $1.25 and a twelve month high of $3.95.

Metagenomi (NASDAQ:MGX - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.02). The firm had revenue of $3.91 million for the quarter, compared to analyst estimates of $7.33 million. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. As a group, equities research analysts predict that Metagenomi will post -2.46 EPS for the current year.

Metagenomi Company Profile

Metagenomi, Inc NASDAQ: MGX is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company's proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi's technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.